Reinhart Partners LLC. Has $69.13 Million Stake in Lantheus Holdings, Inc. $LNTH

Reinhart Partners LLC. reduced its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,347,756 shares of the medical equipment provider’s stock after selling 55,903 shares during the quarter. Lantheus makes up approximately 2.2% of Reinhart Partners LLC.’s holdings, making the stock its 21st largest holding. Reinhart Partners LLC.’s holdings in Lantheus were worth $69,127,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Elevation Point Wealth Partners LLC bought a new position in Lantheus in the 2nd quarter valued at $26,000. First Horizon Corp bought a new stake in shares of Lantheus during the third quarter worth $26,000. Osterweis Capital Management Inc. acquired a new stake in shares of Lantheus in the second quarter valued at $36,000. Tripletail Wealth Management LLC bought a new position in shares of Lantheus in the third quarter valued at about $68,000. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after buying an additional 698 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Trading Down 1.8%

LNTH opened at $64.25 on Friday. The firm has a 50 day simple moving average of $62.19 and a 200 day simple moving average of $61.02. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $111.29. The company has a market cap of $4.26 billion, a price-to-earnings ratio of 27.00 and a beta of -0.11. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 EPS for the quarter, hitting analysts’ consensus estimates of $1.27. The firm had revenue of $384.01 million during the quarter, compared to analyst estimates of $363.42 million. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.70 EPS. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Mizuho increased their price target on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. The Goldman Sachs Group set a $77.00 price target on shares of Lantheus and gave the company a “neutral” rating in a report on Wednesday, October 8th. Finally, Truist Financial upped their price objective on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.